Antibodies to human papillomavirus types 6, 11, 16 and 18: Vertical transmission and clearance in children up to two years of age
Background: There is a paucity of data on the dynamics of human papillomavirus (HPV) antibodies in children. We aimed to describe the vertical transmission and clearance of antibodies against HPV6, 11, 16 and 18 in children.Methods: We used data from pregnant women recruited into the HERITAGE cohort...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-04-01
|
| Series: | EClinicalMedicine |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S258953702030078X |
| _version_ | 1819030642859442176 |
|---|---|
| author | Monica Zahreddine Marie-Hélène Mayrand Christian Therrien Andrea Trevisan Carole Dagenais Patricia Monnier Louise Laporte Joseph Niyibizi Catherine Deshaies Ana Maria Carceller William Fraser Paul Brassard Jacques Lacroix Marie-Josée Bédard Isabelle Girard François Audibert François Coutlée Helen Trottier |
| author_facet | Monica Zahreddine Marie-Hélène Mayrand Christian Therrien Andrea Trevisan Carole Dagenais Patricia Monnier Louise Laporte Joseph Niyibizi Catherine Deshaies Ana Maria Carceller William Fraser Paul Brassard Jacques Lacroix Marie-Josée Bédard Isabelle Girard François Audibert François Coutlée Helen Trottier |
| author_sort | Monica Zahreddine |
| collection | DOAJ |
| description | Background: There is a paucity of data on the dynamics of human papillomavirus (HPV) antibodies in children. We aimed to describe the vertical transmission and clearance of antibodies against HPV6, 11, 16 and 18 in children.Methods: We used data from pregnant women recruited into the HERITAGE cohort study between 2009 and 2012 who were positive for HPV-DNA at baseline. Dried blood spots were collected during the first trimester in pregnant participants, and at birth, 6, 12, and 24 months of age in children. The level of total immunoglobulin G (IgG) against HPV6, 11, 16 and 18 were measured using Luminex immunoassays. Spearman's coefficients were used to correlate HPV antibody levels between newborns and mothers. Panel and Kaplan-Meier graphics described antibody dynamics in the first 24 months of life.Findings: Antibodies from newborns and mothers (n = 58 pairs) were moderately to highly correlated with coefficients of 0·81 (95% confidence intervals (CI):0·70–0·88), 0·68 (95% CI:0·5–0·80), 0·90 (95% CI:0·83–0·94) and 0·85 (95% CI:0·76–0·91) against HPV6, 11, 16 and 18, respectively. In newborns seropositive at birth, anti-HPV antibodies were cleared by 80% and 100% at 12 and 24 months, respectively. Only two children presented detectable HPV antibodies at 24 months. The first child had no detectable antibodies at birth and the second presented increasing levels after two undetected measures.Interpretation: Correlation between mother and newborn IgG antibodies against HPV suggests vertical transfer. Most children cleared anti-HPV antibodies within six to 12 months.Funding: The Canadian Institutes of Health Research (CIHR) Keywords: Human papillomavirus, Serology, Mother-newborn correlation, Vertically acquired immunity, Antibody clearance, Antibody dynamics |
| first_indexed | 2024-12-21T06:33:24Z |
| format | Article |
| id | doaj.art-e516ec55e40d4ca4bb8fe311537214ea |
| institution | Directory Open Access Journal |
| issn | 2589-5370 |
| language | English |
| last_indexed | 2024-12-21T06:33:24Z |
| publishDate | 2020-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EClinicalMedicine |
| spelling | doaj.art-e516ec55e40d4ca4bb8fe311537214ea2022-12-21T19:12:56ZengElsevierEClinicalMedicine2589-53702020-04-0121Antibodies to human papillomavirus types 6, 11, 16 and 18: Vertical transmission and clearance in children up to two years of ageMonica Zahreddine0Marie-Hélène Mayrand1Christian Therrien2Andrea Trevisan3Carole Dagenais4Patricia Monnier5Louise Laporte6Joseph Niyibizi7Catherine Deshaies8Ana Maria Carceller9William Fraser10Paul Brassard11Jacques Lacroix12Marie-Josée Bédard13Isabelle Girard14François Audibert15François Coutlée16Helen Trottier17Department of Social and Preventive Medicine, Université de Montréal, Montreal, Canada; Sainte-Justine University Hospital Center, Université de Montréal, Montreal, CanadaDepartment of Social and Preventive Medicine, Université de Montréal, Montreal, Canada; Department of Obstetrics and Gynecology, Université de Montréal and CRCHUM, Montreal, CanadaLaboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, CanadaDepartment of Social and Preventive Medicine, Université de Montréal, Montreal, Canada; Sainte-Justine University Hospital Center, Université de Montréal, Montreal, CanadaLaboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, CanadaDepartment of Obstetrics and Gynecology, McGill University Health Centre, Montreal, CanadaSainte-Justine University Hospital Center, Université de Montréal, Montreal, CanadaDepartment of Social and Preventive Medicine, Université de Montréal, Montreal, Canada; Sainte-Justine University Hospital Center, Université de Montréal, Montreal, CanadaSainte-Justine University Hospital Center, Université de Montréal, Montreal, CanadaDepartment of Pediatrics, Sainte-Justine University Hospital Center, Université de Montréal, Montreal, CanadaDepartment of Obstetrics and Gynecology, Centre de recherche du Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, CanadaDivision of Clinical Epidemiology, McGill University Health Center, Montreal, CanadaDepartment of Pediatrics, Sainte-Justine University Hospital Center, Université de Montréal, Montreal, CanadaDepartment of Obstetrics and Gynecology, Université de Montréal and CRCHUM, Montreal, CanadaDepartment of Obstetrics and Gynecology, St-Mary's Hospital Center, McGill University, Montreal, CanadaDepartment of Obstetrics and Gynecology, Sainte-Justine University Hospital Center, Université de Montréal, Montreal, CanadaDepartment of Microbiology, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montreal, CanadaDepartment of Social and Preventive Medicine, Université de Montréal, Montreal, Canada; Sainte-Justine University Hospital Center, Université de Montréal, Montreal, Canada; Corresponding author at: Sainte-Justine Hospital Research Center, 3175 Côte-Sainte-Catherine Street, Room B.17.002, Montreal (QC), H3T 1C5, Canada.Background: There is a paucity of data on the dynamics of human papillomavirus (HPV) antibodies in children. We aimed to describe the vertical transmission and clearance of antibodies against HPV6, 11, 16 and 18 in children.Methods: We used data from pregnant women recruited into the HERITAGE cohort study between 2009 and 2012 who were positive for HPV-DNA at baseline. Dried blood spots were collected during the first trimester in pregnant participants, and at birth, 6, 12, and 24 months of age in children. The level of total immunoglobulin G (IgG) against HPV6, 11, 16 and 18 were measured using Luminex immunoassays. Spearman's coefficients were used to correlate HPV antibody levels between newborns and mothers. Panel and Kaplan-Meier graphics described antibody dynamics in the first 24 months of life.Findings: Antibodies from newborns and mothers (n = 58 pairs) were moderately to highly correlated with coefficients of 0·81 (95% confidence intervals (CI):0·70–0·88), 0·68 (95% CI:0·5–0·80), 0·90 (95% CI:0·83–0·94) and 0·85 (95% CI:0·76–0·91) against HPV6, 11, 16 and 18, respectively. In newborns seropositive at birth, anti-HPV antibodies were cleared by 80% and 100% at 12 and 24 months, respectively. Only two children presented detectable HPV antibodies at 24 months. The first child had no detectable antibodies at birth and the second presented increasing levels after two undetected measures.Interpretation: Correlation between mother and newborn IgG antibodies against HPV suggests vertical transfer. Most children cleared anti-HPV antibodies within six to 12 months.Funding: The Canadian Institutes of Health Research (CIHR) Keywords: Human papillomavirus, Serology, Mother-newborn correlation, Vertically acquired immunity, Antibody clearance, Antibody dynamicshttp://www.sciencedirect.com/science/article/pii/S258953702030078X |
| spellingShingle | Monica Zahreddine Marie-Hélène Mayrand Christian Therrien Andrea Trevisan Carole Dagenais Patricia Monnier Louise Laporte Joseph Niyibizi Catherine Deshaies Ana Maria Carceller William Fraser Paul Brassard Jacques Lacroix Marie-Josée Bédard Isabelle Girard François Audibert François Coutlée Helen Trottier Antibodies to human papillomavirus types 6, 11, 16 and 18: Vertical transmission and clearance in children up to two years of age EClinicalMedicine |
| title | Antibodies to human papillomavirus types 6, 11, 16 and 18: Vertical transmission and clearance in children up to two years of age |
| title_full | Antibodies to human papillomavirus types 6, 11, 16 and 18: Vertical transmission and clearance in children up to two years of age |
| title_fullStr | Antibodies to human papillomavirus types 6, 11, 16 and 18: Vertical transmission and clearance in children up to two years of age |
| title_full_unstemmed | Antibodies to human papillomavirus types 6, 11, 16 and 18: Vertical transmission and clearance in children up to two years of age |
| title_short | Antibodies to human papillomavirus types 6, 11, 16 and 18: Vertical transmission and clearance in children up to two years of age |
| title_sort | antibodies to human papillomavirus types 6 11 16 and 18 vertical transmission and clearance in children up to two years of age |
| url | http://www.sciencedirect.com/science/article/pii/S258953702030078X |
| work_keys_str_mv | AT monicazahreddine antibodiestohumanpapillomavirustypes61116and18verticaltransmissionandclearanceinchildrenuptotwoyearsofage AT mariehelenemayrand antibodiestohumanpapillomavirustypes61116and18verticaltransmissionandclearanceinchildrenuptotwoyearsofage AT christiantherrien antibodiestohumanpapillomavirustypes61116and18verticaltransmissionandclearanceinchildrenuptotwoyearsofage AT andreatrevisan antibodiestohumanpapillomavirustypes61116and18verticaltransmissionandclearanceinchildrenuptotwoyearsofage AT caroledagenais antibodiestohumanpapillomavirustypes61116and18verticaltransmissionandclearanceinchildrenuptotwoyearsofage AT patriciamonnier antibodiestohumanpapillomavirustypes61116and18verticaltransmissionandclearanceinchildrenuptotwoyearsofage AT louiselaporte antibodiestohumanpapillomavirustypes61116and18verticaltransmissionandclearanceinchildrenuptotwoyearsofage AT josephniyibizi antibodiestohumanpapillomavirustypes61116and18verticaltransmissionandclearanceinchildrenuptotwoyearsofage AT catherinedeshaies antibodiestohumanpapillomavirustypes61116and18verticaltransmissionandclearanceinchildrenuptotwoyearsofage AT anamariacarceller antibodiestohumanpapillomavirustypes61116and18verticaltransmissionandclearanceinchildrenuptotwoyearsofage AT williamfraser antibodiestohumanpapillomavirustypes61116and18verticaltransmissionandclearanceinchildrenuptotwoyearsofage AT paulbrassard antibodiestohumanpapillomavirustypes61116and18verticaltransmissionandclearanceinchildrenuptotwoyearsofage AT jacqueslacroix antibodiestohumanpapillomavirustypes61116and18verticaltransmissionandclearanceinchildrenuptotwoyearsofage AT mariejoseebedard antibodiestohumanpapillomavirustypes61116and18verticaltransmissionandclearanceinchildrenuptotwoyearsofage AT isabellegirard antibodiestohumanpapillomavirustypes61116and18verticaltransmissionandclearanceinchildrenuptotwoyearsofage AT francoisaudibert antibodiestohumanpapillomavirustypes61116and18verticaltransmissionandclearanceinchildrenuptotwoyearsofage AT francoiscoutlee antibodiestohumanpapillomavirustypes61116and18verticaltransmissionandclearanceinchildrenuptotwoyearsofage AT helentrottier antibodiestohumanpapillomavirustypes61116and18verticaltransmissionandclearanceinchildrenuptotwoyearsofage |